Through the development of a multidisciplinary musculoskeletal institute, we have created a model that facilitates coordination of care of complex patients between medical and surgical subspecialists, physical therapists, dieticians and social workers. A case is presented to demonstrate the improved care experience for both patients and providers and to share our learnings more broadly. The…
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
Research in The New England Journal of Medicine has opened new avenues for exploring the pathophysiology of disease flares in rheumatoid arthritis.1 Through longitudinal genomic analysis, researchers have identified a naive B cell signature prior to rheumatoid arthritis flares, as well as a type of mesenchymal cell, that may play an important role in flare…
Dr. Schiopu has experienced the COVID-19 pandemic response from both clinical and research perspectives. She recently discussed her experiences with The Rheumatologist.
A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…
ACR CONVERGENCE 2020—In her ARP keynote address on Friday, Nov. 6, Empowering Patients to Make an Impact on the Future of Healthcare, Jen Horonjeff, PhD, described a study in which researchers gathered data on pain and activity level among arthritis patients. In her view, the study provided a cautionary tale. Researchers expected the study subjects…
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.
The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.
Three experts discuss the current evidence on potential pathogenic mechanisms underlying preclinical RA autoimmunity and subsequent active disease.